The company said it completed a public offering of November 21, 2025 Floating Rate Notes due 2027, 3.875% Notes due 2027, and 4.200% Notes due 2030, among seven series of notes in total.

1. 01

   The company said it completed a public offering of November 21, 2025 Floating Rate Notes due 2027, 3.875% Notes due 2027, and 4.200% Notes due 2030, among seven series of notes in total.

2. 02

   Pfizer completed the offering of $500,000,000 Floating Rate Notes due 2027, $1,000,000,000 3.875% Notes due 2027, $1,000,000,000 4.200% Notes due 2030, and $1,250,000,000 4.500% Notes due 2032 in aggregate principal amount.

3. 03

   The company also disclosed aggregate principal amounts of $1,250,000,000 4.875% Notes due 2035, $500,000,000 5.600% Notes due 2055, and $500,000,000 5.700% Notes due 2065.

4. 04

   The company entered into an underwriting agreement and a pricing agreement on November 18, 2025 with Citigroup Global Markets Inc., Deutsche Bank Securities Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC. The notes were offered under the Form S-3 shelf registration statement.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.